Ключові слова
гіперліпідемія
поліморфізм гена SLCO1B1
Як цитувати
Анотація
Вивчали поширеність поліморфізму гена SLCO1B1 у пацієнтів кардіологічного відділення з гіперліпідемією БПМЦ УК №1. Було виявлено 70 (55,1%) носіїв «дикого» типу с.521ТТ; 47 (37%) пацієнтів з генотипом с.521ТС та 10 (7,9%) пацієнтів з генотипом с.521СС. Розробленй алгоритм для індивідуального підбору максимальної дози статину та рекомендований до практичного застосування експертами Європейського наукового фонду.Посилання
Buhaienko V.V. (2014). Statiny v pervichnoi i vtorichnoi profilaktike serdechno-sosudistogo riska: novyi vzgliad na staruiu problemu [Statins in primary and secondary prevention of cardiovascular risk: a new look at the old problem]. Ukrainskii kardoil. Zhurnal – Ukrainian cardiologist magazine. 3: 103–108. [in Russian].
Khokhlov A.A., Sychev D.A., Sirotkina A.M. (2016). Aspekty bezopasnoho primeneniia statinov: mezhlekarstvennoie vzaimodeistviie, farmakoheneticheskiie voprosy [Aspects of safe use of statins: inter-drug interactions, pharmacogenetic issues]. Universum: Meditsina i farmakologiia: electron. nauchn. zhurn. – Universum: Medicine and Pharmacology: electron. scientific. journal. 1–2 (24). URL: http://7universum.com/ru/med/archive/item/2950 [in Russian].
Banach M., Rizzo M., P.P. Toth, M. Farnier, M.H. Davidson, K. Al-Rasadi et al. (2015). Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch. Med. Sci. 11 (1): 1–23.
Voora D., Shah S.H., Spasojevic I., Ali S., C.R. Reed, B.A. Salisbury et al. (2009). The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54 (17): 1609–1616.
Kazakov R.E., Yevteev V.A., Muslimova O.V., Muslimova O.V., Mazerkina I.A. (2016). Znacheniie heneticheskikh faktorov v prohnozirovanii pobochnykh deistvii statinov [The importance of genetic factors in predicting the side effects of statins]. Mezhdunarodnyi zhurnal prikladnykh i fundamentalnych issledovanii – International Journal of Applied and Fundamental Research. 8: 691–698 [in Russian].
Shuev H.N., Sychev D.A., Hrachev A.V. (2015). Polimorfizm hena SLCO1B1, assotsiirovannyi s razvitiem statin-indutsirovaanoi miopatii, uroven vitamina D u rossiiskikh patsientov s hiperlipidemiiami [Polymorphism of the SLCO1B1 gene associated with the development of statin-induced myopathy, the level of vitamin D in Russian patients with hyperlipidemia] Kreativnaia kardiolohiia – Creative cardiology. 4: 40–45.
Bays H. (2006). Statinsafety: an over view and assessment of the data. Am. J. Cardiol. 97 (8A): 6–26.
Carr D.F., O’Meara H., Jorgensen A.L., Campbell J., Hobbs M., McCann G. et al. (2013). SLCO1B1 Genetic variant associated with statin-induced myopathy: A proof-of concept study using the clinical practice research datalink. Clinical Pharmacology & Therapeutics. 94 (6): 695–670.
FDa expands advice on statin Risks http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCm293705.pdf
Linde R., Peng L., Desai M., Feldman D. (2010). The role of vitamin D and SLCO1B1·5 gene polymorphism in statin-associated myalgias. Dermatoendocrinology. 2 (2): 77–84.
Seredenin S.B. (2004). Lektsii po farmakohenetike [Lectures on pharmacogenetics]. Moskow: MIA. 303 pp.[in Russian].
Guidance for industry clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling. Electronic resource: http: // www.fda.gov/downloads/ gs/guidancecomplianceregulatoryinformation/guidances/ ucm337169.pdf
Tirona R.G., Leake B.F., Merino G., Kim R.B. (2001). Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European and African-Americans. The Journal of Biological Chemistry. 276 (38): 35669–35675.
Link E., Parish S., Armitage J., Bowman L., Heath S., Matsuda F. et al. (2008). SLCO1B1 variants and statin-induced myopathy a genomewide study. New Engl. J. Med. 359 (8): 789–799.
Sirotkina A.M., Khokhlov A.L., Voronina Ye.A., Mohutov M.S., Driazhenkova I.V., Tzariova I.N. et al. (2013). Rasprostranennost polimorfnoho markera hena SLCO1B1 u patsientov s dislipidemiiei I sistemnym aterosklerosom [Prevalence of the polymorphic marker of the gene in patients with dyslipidemia and systemic atherosclerosis]. Kardiovaskuliarnaia terapiia i profilaktika – Cardiovascular therapy and prevention. 12 (april). Spetsialnyi vypusk. 22 [in Russian].
Kukes B.H. (Eds.). (2009). Klinicheskaia farmakolohiia: uchebnik dlia vuzov [Clinical pharmacology: a textbook for universities]. (4 ed.). 1056 pp. [In Russian].
Sortica V.A., Fiegenbaum M., Lima L.O,. Van der Sand C.R., Van der Sand L.C., Ferreira M.E. et al (2012). SLCO1B1 gene variability influences lipid-lowering efficacy on silvastatin therapy in Southern Brazilians. Clin. Chem. Lab. Med. 50 (3): 441.
Becquemont L., Alfirevic A., Amstutz U., Brauch H., Jacqz-Aigrain E., Laurent-Puig P. et al. (2011). Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB. Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics. № 12 (1): 113–124.